<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152956">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01804790</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 23</org_study_id>
    <nct_id>NCT01804790</nct_id>
  </id_info>
  <brief_title>Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer</brief_title>
  <acronym>Néofirinox</acronym>
  <official_title>- Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <authority>France: ANSM - French Health Products Safety Agency</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      National, multi-center, open-label,randomized, 2-arm phase III superiority trial, comparing
      neoadjuvant chemotherapy (CT) with mFolfirinox followed by preoperative chemoradiotherapy
      (CRT), versus preoperative CRT in patients with locally advanced rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology This is a biomedical research, national, multicenter, open-label randomized,
      2-arm phase III superiority trial, comparing neoadjuvant CT with mFolfirinox then
      preoperative CRT, versus immediate preoperative CRT, in patients with locally advanced
      rectal cancer Randomized Phase III study with stopping rules Stratification : center,
      gender, tumor location in the rectum (&lt; 6 cm from anal verge versus ≥ 6 cm), initial stage
      (cT3 vs cT4, and cN0 vs cN+)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the 3-year disease-free survival between the investigational arm and the control arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>7 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall survival will be defined as the time from randomisation to the time of occurrence of the first death regardless to its cause.  Patients alive at the time of analysis will be censored at the date of the last follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Cancer of the Rectum</condition>
  <arm_group>
    <arm_group_label>Arm A : Radiotherapy + capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemoradiotherapy 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine 800 mg/m2 twice daily 5 days/7, excluding weekends), then 6-8 weeks after chemoradiation, surgery with total mesorectal excision (TME), followed by adjuvant chemotherapy for 6 months, either mFolfox6 or capecitabine, depending on ypTNM and the center's choice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : Chemotherapy then radiochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:  Chemotherapy mFolfirinox
Investigational arm: Neoadjuvant CT mFolfirinox, 6 cycles (ca. 3 months; each cycle = 2 weeks):
oxaliplatin: 85 mg/m2 in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m2 simultaneously in 2 hours at D1 during the irinotecan infusion 5FU : 2400 mg/m2 continuous infusion during 48 hours (1200 mg/m2 at D1 and D2), every 14 days during 2 months (4 cycles).
Then followed by 5 weeks of chemoradiotherapy 50 Gy (2 Gy/session, , 5 sessions per week) + capecitabine 800mg/m2 twice daily 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, followed by 3 months of adjuvant chemotherapy, either mFolfox6 or capecitabine depending on ypTNM and center's choice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFolfirinox</intervention_name>
    <description>Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles:oxaliplatin: 85 mg/m2 in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m2 simultaneously in 2 hours at D1 during the irinotecan infusion 5FU  : 2400 mg/m2 continuous infusion during 48 hours (1200 mg/m2 at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800mg/m2 bid 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on ypTNM and center choice.</description>
    <arm_group_label>Arm B : Chemotherapy then radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy 50Gy</intervention_name>
    <description>5 radiations per week of 2 Gy for 5 weeks</description>
    <arm_group_label>Arm A : Radiotherapy + capecitabine</arm_group_label>
    <arm_group_label>Arm B : Chemotherapy then radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1600mg/m2 (800mg/m2 twice daily) for 5 weeks</description>
    <arm_group_label>Arm A : Radiotherapy + capecitabine</arm_group_label>
    <arm_group_label>Arm B : Chemotherapy then radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME surgery</intervention_name>
    <arm_group_label>Arm A : Radiotherapy + capecitabine</arm_group_label>
    <arm_group_label>Arm B : Chemotherapy then radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFolfox6 or capecitabine</intervention_name>
    <description>oxaliplatine 85mg/m2 (day 1 of cycle; perfusion in 2h), folinic acid 400mg/m2 (day 1 of cycle perfusion in 2h), 5-fluorouracil (bolus 4OOmg/m2 in 10min and 2400mg/m2 perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500mg/m2/day (Each cycle consists of 1250mg/m2 twice daily for D1-14 then pause therapeutic from D15-21).  Arm A - 8 cycles; Arm B 4 cycles.</description>
    <arm_group_label>Arm A : Radiotherapy + capecitabine</arm_group_label>
    <arm_group_label>Arm B : Chemotherapy then radiochemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histogically proven rectal adenocarcinoma

          -  Stages cT3 with risk of local recurrence or cT4, M0 and for which a multidisciplinary
             meeting recommend preoperative CRT

          -  Resectable tumor, or considered as potentially resectable after CRT

          -  No distant metastases

          -  Patient eligible for surgery

          -  Patient aged from 18 to 75 years

          -  WHO/ECOG performance status 0/2.

          -  No heart failure or coronary heart disease symptoms (even controlled).

          -  No peripheral neuropathy &gt; grade 1

          -  No prior radiotherapy of the pelvis for any reason and no previous CT

          -  No major comorbidity that may preclude the delivery of treatment and no active
             infection (HIV or chronic hepatitis B or C).

          -  Adequate contraception in fertile patients.

          -  Adequate hematologic function

          -  Adequate hepatic function

          -  Signed written informed consent

        Exclusion Criteria:

          -  Metastatic disease

          -  Unresectable rectal cancer, including prostatic involvement or extension to pelvic
             floor muscles

          -  Contraindication to 5-FU, or to oxaliplatin or to irinotecan, including Gilbert
             disease or genotype UGT1A1

          -  Medical history of chronic diarrhea or inflammatory disease of the  colon or  rectum

          -  Medical history of angina pectoris or myocardial infarction

          -  Progressive active infection or any other severe medical condition that could
             jeopardize treatment administration

          -  Other concomitant cancer, or medical history of cancer other than treated in situ
             cervical carcinoma or basocellular carcinoma or spinocellular carcinoma

          -  Patient included in another clinical trial testing an investigational agent.

          -  Pregnant or breast-feeding woman.

          -  Persons deprived of liberty or under guardianship or incapable of giving consent

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol or follow-up schedule.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry CONROY, PROF</last_name>
    <role>Principal Investigator</role>
    <affiliation>centre Alexis Vautrin les Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beata JUZYNA</last_name>
    <phone>33144235567</phone>
    <email>b-juzyna@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Prive Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pascal ARTRU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry CONROY, PROF</last_name>
    </contact>
    <investigator>
      <last_name>Thierry CONROY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric FRANCOIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint-brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre-Luc ETIENNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meher BEN ABDELGHANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 4, 2013</lastchanged_date>
  <firstreceived_date>March 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectum</keyword>
  <keyword>cancer</keyword>
  <keyword>locally advanced</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
